Investor Menu
View all news

Seagen to Highlight Data from Expanding Oncology Portfolio at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

04/28/2022

– Data from 26 abstracts, including four oral presentations, underscore Seagen progress toward addressing unmet needs across multiple tumor types –

BOTHELL, Wash.--(BUSINESS WIRE)-- Seagen Inc. (Nasdaq:SGEN) today announced upcoming presentations of new data from its expanding pipeline of marketed and investigational therapies at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 3-7, 2022 in Chicago. The accepted abstracts demonstrate the growth of Seagen’s portfolio and clinical progress across multiple cancer types, including cervical and urothelial cancers and pediatric and adult Hodgkin lymphoma. Groundbreaking overall survival data for Stage III/IV Hodgkin lymphoma patients who were treated with ADCETRIS® (brentuximab vedotin) as part of a first-line therapy combination will be detailed in one of three oral presentations for the antibody-drug conjugate medicine.

Other important data include interim results from the dose-expansion cohorts of the innovaTV 205 trial of TIVDAK® (tisotumab vedotin-tftv) in combination with other anticancer agents in patients with recurrent metastatic cervical cancer, which will also be featured in an oral presentation. Long-term outcomes from the phase 3 EV-301 trial of PADCEV® (enfortumab vedotin-ejfv) in patients with previously treated advanced urothelial carcinoma will be shared in a poster discussion.

“Significant improvements in overall and event-free survival are important new findings in adult and pediatric Hodgkin lymphoma patients, respectively,” said Roger Dansey, M.D., Chief Medical Officer at Seagen. “We look forward to the presentations and plan to submit supplemental applications to the Food and Drug Administration to update overall survival in the ADCETRIS prescribing information for Hodgkin lymphoma and expand its indication to include children.”

Key data presentations for Seagen include:

Presentations of Company-Sponsored Trials

Abstract Title 

Abstract #

Presentation 

Lead Author 

ADCETRIS® (brentuximab vedotin)

First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with Stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1

7503

Oral
Friday, June 3
2 p.m. CT

S. M. Ansell

Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Safety and efficacy results from the safety run-in period of the phase 3 ECHELON-3 study

7559

Poster
Saturday, June 4
8 a.m. CT

N. L. Bartlett

Updated safety and efficacy data from an open-label, phase 1/2 study of frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) in pediatric patients with advanced-stage classical Hodgkin lymphoma (cHL)

10000

Oral
Monday, June 6
3 p.m. CT 

A. R. Franklin

The impact of classic Hodgkin lymphoma (cHL) on informal caregivers: Results from the cHL: Real-world observations from physicians, patients, and caregivers on the disease and its treatment (CONNECT) study

 

E24004

 

Online Publication

D. R. Flora

PADCEV® (enfortumab vedotin-ejfv)

Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

4516

Poster Discussion
Saturday, June 4
5:04 p.m. CT

J. E. Rosenberg

Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible

4582

Poster
Saturday, June 4
1:15 p.m. CT

D. P. Petrylak

Benchmarking maintenance therapy survival in first-line advanced urothelial carcinoma using disease modeling

4575

Poster
Saturday, June 4
1:15 p.m. CT

M. D. Galsky

Real world treatment patterns and clinical outcomes with first-line therapy in cisplatin-eligible and ineligible patients with advanced urothelial carcinoma

4565

Poster
Saturday, June 4
1:15 p.m. CT

G. P. Sonpavde

TIVDAK ® (tisotumab vedotin-tftv)

Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis

5532

Poster
Saturday, June 4
1:15 p.m. CT

K. Sonawane

Cervical cancer geographical burden analyzer: An interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic cervical cancer

5523

Poster Discussion
Saturday, June 4
4:30 p.m. CT

T. Castellano

Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205

5507

Oral
Monday, June 6
10:12 a.m. CT

D. Lorusso

Productivity losses under various second-line recurrent or metastatic cervical cancer treatment scenarios in the United States

E17520

Online Publication

J. Ting

Patterns of care in Medicaid-enrollees with recurrent or metastatic cervical cancer

E17525

Online Publication

C. A. Leath

TIVDAK® (tisotumab vedotin-tftv) Trials in Progress

Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) + pembrolizumab (pembro) + carboplatin (carbo) ± bevacizumab (bev) in recurrent/metastatic cervical cancer (r/mCC)

TPS5603

Poster
Saturday, June 4
1:15 p.m. CT

I. Vergote

innovaTV 207: New combination dosing cohorts in the open label phase 2 study of tisotumab vedotin in solid tumors

TPS6100

Poster
Monday, June 6
1:15 p.m. CT

X. Le

TUKYSA® (tucatinib) Trials in Progress

Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)

TPS1108

Poster
Monday, June 6
8 a.m. CT

E. P. Hamilton

Phase 2 trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress)

TPS1111

Poster
Monday, June 6
8 a.m. CT

I. E. Krop

Disitamab vedotin

Preliminary results of a phase Ib/II combination study of RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with locally advanced or metastatic urothelial carcinoma

4518

Poster Discussion
Saturday, June 4
5:26 p.m. CT

X. Sheng

A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma

4519

Poster Discussion
Saturday, June 4
5:26 p.m. CT

H. Xu

RC48-ADC for metastatic urothelial carcinoma with HER2 -positive: Combined analysis of RC48-C005 and RC48-C009 trials

 

4520

Poster Discussion
Saturday, June 4
5:26 p.m. CT

X. Sheng

Pipeline Trials in Progress

Phase 1 study of SGN-B7H4V, a novel, investigational vedotin antibody–drug conjugate directed to B7-H4, in patients with advanced solid tumors (SGNB7H4V-001, trial in progress)

TPS3155

Poster
Sunday, June 5
8 a.m. CT

A. Patnaik

Phase 1 study of SGN-PDL1V, a novel, investigational vedotin antibody–drug conjugate directed to PD-L1, in patients with advanced solid tumors (SGNPDL1V-001, trial in progress)

TPS3154

Poster
Sunday, June 5
8 a.m. CT

A. Patnaik

Phase 1 study of SGN-ALPV, a novel, investigational vedotin antibody–drug conjugate directed to ALPP/ALPPL2 in advanced solid tumors (SGNALPV-001, trial in progress)

TPS3159

Poster
Sunday, June 5
8 a.m. CT

N. Lakhani

Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress)

TPS1127

Poster
Monday, June 6
8 a.m. CT

J. L. Meisel

Presentations of Investigator-Sponsored or Cooperative Group Trials

Abstract Title 

 Abstract #

 Presentation

Lead Author 

Brentuximab vedotin and association with event-free survival (EFS) in children with newly diagnosed high-risk Hodgkin lymphoma (HL): A report from the Children's Oncology Group phase 3 study AHOD1331 (NCT 02166463)

7504

Oral
Friday, June 3
2:12 p.m. CT

S. M. Castellino

Brentuximab vedotin and nivolumab alone and then combined with rituximab, cyclophosphamide, doxorubicin, and prednisone for frontline therapy of patients with primary mediastinal large B-cell lymphoma

TPS7589

Poster
Saturday, June 4
8 a.m. CT

R. E. Steiner

About Seagen

Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on our marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.

Forward-Looking Statements

Certain statements made in this press release are forward looking, such as those, among others, relating to the company’s pipeline and the therapeutic potential of ADCETRIS, PADCEV, TUKYSA, TIVDAK, disitamab vedotin, ladiratuzumab vedotin and the company’s other product candidates, including their efficacy, safety and potential therapeutic uses. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include without limitation the difficulty and uncertainty of pharmaceutical product development, including the risks that the company may experience delays in its clinical trials or otherwise experience failures or setbacks in its clinical development programs due to lack of efficacy, adverse events or other factors, and that adverse regulatory actions may occur. More information about the risks and uncertainties faced by Seagen is contained under the caption “Risk Factors” included in the company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

For Media
David Caouette
Vice President, Corporate Communications
(310) 430-3476
dcaouette@seagen.com

For Investors
Peggy Pinkston
Senior Vice President, Investor Relations
(425) 527-4160
ppinkston@seagen.com

Source: Seagen Inc.

View all news